Skip to main content
[Preprint]. 2024 Nov 18:2024.11.18.624183. [Version 1] doi: 10.1101/2024.11.18.624183

Figure 3. CD73 restrains transcriptional activity of patient-specific β-catenin mutants.

Figure 3.

(A) Variety and frequency of missense mutations in exon 3 of CTNNB1 in endometrial cancer patients, collected from 5 patient cohorts (The Cancer Genome Atlas (TCGA), Memorial Sloan Kettering Cancer Center (MSK), Clinical Proteomic Tumor Analysis Consortium (CPTAC), the University of North Carolina (UNC), and the University of Texas MD Anderson Cancer Center (MDA). Asterisks indicate patient-specific CTNNB1 mutations which expression vectors were developed and used in our studies. (B, D) Immunoblots of myc-tagged wildtype (WT) and patient-specific β-catenin mutants and CD73 expression in HEC-1-A and Ishikawa cells. (C, E) TCF/LEF reporter activity of WT and patient-specific β-catenin mutants in HEC-1-A and Ishikawa cells. (E) Ishikawa cells were transfected with AdV NT5E or AdV empty vector DNA. (B) and (D) are representative immunoblots from two independent experiments. (C) and (E) are pooled data from n = 2 independent experiments of 5–6 replicates per experiment. Data represent the mean ± SEM. *P < 0.05, ** P < 0.01, ***P < 0.0005, ****P < 0.0001; 2-way ANOVA with Sidak’s post test.